#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians currently lack evidence-based dosing guidelines for oral THC, making this dose-finding trial clinically significant for establishing safe and effective therapeutic ranges. Results from this research will enable more precise patient dosing recommendations, potentially improving treatment outcomes while reducing adverse effects from sub- or supra-therapeutic dosing. This type of pharmacokinetic data is essential for integrating cannabis into mainstream clinical practice with the same rigor applied to other medications.
Avicanna is sponsoring a University of Calgary clinical trial designed to establish dose-response relationships for oral THC and characterize individual variability in therapeutic response. This research addresses a significant gap in cannabis medicine by generating rigorous, high-resolution data on optimal THC dosing and the factors that influence individual patient responses. Understanding the therapeutic window for oral THC is clinically important because current prescribing practices often rely on limited evidence, leading to inconsistent dosing recommendations and variable patient outcomes. The trial’s focus on inter-individual differences will help clinicians predict which patients may benefit from THC at lower doses and which may require higher doses for therapeutic effect. For clinical practice, establishing evidence-based dosing guidelines will improve treatment efficacy, reduce adverse effects from suboptimal dosing, and strengthen the scientific foundation for cannabis-based therapeutics in regulated medical settings.
“When we finally have rigorous dose-response data for oral THC, we’ll be able to move beyond the guesswork that’s defined cannabis medicine for decades, and that matters because the difference between a therapeutic dose and one that causes anxiety or impaired cognition can be just 2.5 milligrams for some patients.”
🔬 While industry-sponsored dose-finding studies can provide clinically valuable pharmacokinetic data to optimize therapeutic THC administration, clinicians should remain cognizant that manufacturer involvement may introduce bias in study design, outcome selection, or dissemination practices. The inherent variability in cannabis metabolism due to genetic factors, drug interactions, and individual differences in cannabinoid sensitivity means that population-level dose recommendations may not directly translate to individual patient needs in clinical settings. Additionally, the distinction between establishing a therapeutic window for symptom management versus identifying safety thresholds requires rigorous characterization of both efficacy and adverse outcomes across diverse patient populations. As this data emerges, practitioners should integrate findings with existing evidence on THC dosing while maintaining realistic expectations that optimal dosing will likely remain individualized and require careful titration and patient monitoring rather than formulaic application of study-derived recommendations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: